• Home
• Responsibility
• Our values and policies
• Developing countries
• Preferential pricing

Preferential pricing

We have offered sustainable preferential pricing for ARVs since 1997 and for vaccines for over 20 years.

Our AIDS medicines and anti-malarials are available at not-for-profit prices to public sector customers and not-for-profit organisations in 64 countries - all the Least Developed Countries (LDCs) and all of sub-Saharan Africa (SSA). In addition, all private employers in sub-Saharan Africa who provide care and treatment to their uninsured staff can purchase our ARVs at not-for-profit preferential prices. All projects fully funded by the Global Fund to Fight AIDS TB and Malaria, are also eligible, which means that our not-for-profit prices are now available in over 100 countries, including all countries covered by the US President’s Emergency Plan for AIDS Relief (PEPFAR). Our prices are sustainable – we do not make a profit on them, but we do cover our costs. This means that we can sustain supply of these high-quality products for as long as they are needed. For middle-income developing countries we continue to negotiate public sector prices on a case-by-case basis to improve affordability, either bilaterally, or through the UN-led Accelerating access initiative of which we are a founder member.

Our not-for-profit prices are comparable with generics. Visit the Corporate Responsibility Review for up to date information.

With regard to vaccines, it is widely acknowledged that global immunisation is one of the most successful public health initiatives ever undertaken. It has led to the eradication of smallpox, the potential eradication of polio, and it is estimated to save the lives of up to three million children world-wide each year. We have played a key role in this effort as one of the primary suppliers of vaccines to major international organisations such as WHO, the United Nations Children’s Fund (UNICEF) and the Pan-American Health Organisation (PAHO).

For the latest information on progress see the Corporate Responsibility Review.

Back to top